All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LNP based nucleic acid therapeutics
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $600.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2021
Details:
Takeda will have access to Genevant’s innovative LNP technology to develop nucleic acid therapeutics directed to specified targets in historically inaccessible hepatic stellate cells to treat liver fibrosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 26, 2021
Details:
LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP-721
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EDP-721
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
Enanta Pharmaceuticals announces New Oral Hbv Rna Destabilizer, EDP-721, as an additional component toward functional HBV Cure; expects to initiate phase 1 study mid-2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $470.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2020
Details:
HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda’s discovery portfolio.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The presentations demonstrate superior pharmacological properties of SRT-015 compared to other ASK1 inhibitors, including selonsertib, and provide potential explanations for the failure of selonsertib in clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TXR-611
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TXR-611
Highest Development Status: Preclinical Product Type: Small molecule
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
